Philip Reigan

Philip Reigan Ph D

Associate Professor
Pharmaceutical Sciences
  • Skaggs School of Pharmacy and Pharmaceutical Sciences

Recent Publications

Director, Computational Chemistry and Biology Core Facility

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor Room 2101

Research Interests:

  • Computational-based design of novel small molecules
  • Chemical synthesis of heterocyclic compounds
  • Targeting adaptive proteins and pathways in hypoxia (metabolic reprogramming)
  • Disrupting drug resistance mechanisms in cancer (DNA damage response)

Representative publications:

Matheson CJ, Casalvieri KA, Backos DS, Reigan P. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. ChemMedChem. 2018;13(16):1681-1694.

Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective Targeting of RSK Isoforms in Cancer. Trends Cancer. 2017;3(4):302-312.

Furtek SL, Backos DS, Matheson CJ, Reigan P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016;11(2):308-18.